Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

63.05
-1.3800-2.14%
Pre-market: 63.04-0.0100-0.02%09:14 EDT
Volume:536.69K
Turnover:33.91M
Market Cap:1.80B
PE:161.67
High:65.50
Open:64.55
Low:62.00
Close:64.43
52wk High:66.37
52wk Low:14.27
Shares:28.58M
Float Shares:26.78M
Volume Ratio:0.76
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):-0.1710
ROE:35.97%
ROA:11.86%
PB:38.69
PE(LYR):-368.74

Loading ...

Eton Pharmaceuticals price target raised to $62 from $40 at Craig-Hallum

TIPRANKS
·
Jul 28

Eton Pharmaceuticals (ETON) Stock Looks Overvalued Even After Recent Wins

Simply Wall St.
·
Jul 18

Eton Pharmaceuticals Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 17

Opaleye Management Disposes of 28,315 Eton Pharma Shares Worth $1.06 Million

Reuters
·
Jul 17

Eton Pharmaceuticals initiated with a Buy at Canaccord

TIPRANKS
·
Jul 17

Opaleye Management Sells 126,685 Eton Pharma Shares for $4.8 Million

Reuters
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON), Tarsus Pharmaceuticals (TARS) and Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jul 06

Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jun 27

Eton Pharma director Jennifer McKie Adams disposes of 50,000 common shares for $1.62 million

Reuters
·
Jun 18

Eton Pharmaceuticals shareholders elect two directors at annual meeting

Reuters
·
Jun 10

Eton Pharma CFO Judith Matthews files initial beneficial ownership statement

Reuters
·
Jun 02

Eton Pharma CEO Sean Brynjelsen sells common shares worth $3.87 million

Reuters
·
May 30

Eton Pharma Chief Business Officer David Krempa disposes of 99,999 common shares worth USD 3.24 million

Reuters
·
May 28

Analysts Are Bullish on These Healthcare Stocks: Personalis (PSNL), Eton Pharmaceuticals (ETON)

TIPRANKS
·
May 22

Eton Pharmaceuticals secures US commercialization rights to leishmaniasis drug Impavido

Reuters
·
May 20

Eton Pharmaceuticals Inc - Exclusive U.S. Commercialization Rights to Impavido Effective September 26, 2026

THOMSON REUTERS
·
May 20

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to Impavido® (Miltefosine)

THOMSON REUTERS
·
May 20

Eton Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 16

Eton Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $57 From $52

THOMSON REUTERS
·
May 15

Eton Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15